CardiovascularINTRAMUSCULARGeneric
PRIMAXIN
CILASTATIN SODIUM; IMIPENEM
Standard Dose
EQ 750MG BASE/VIAL;750MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: UNKNOWN Marketing status: Discontinued
Summary
Approval overview PRIMAXIN is listed in Drugs@FDA under application 050630 (NDA).
Review priority: UNKNOWN Marketing status: Discontinued Active ingredient CILASTATIN SODIUM; IMIPENEM Form and strength POWDER;INTRAMUSCULAR - EQ 750MG BASE/VIAL;750MG/VIAL Sponsor MERCK Submission history Latest submission status date: 2009-08-26 00:00:00.
Structured Monograph
Clinical summary
Approval overview PRIMAXIN is listed in Drugs@FDA under application 050630 (NDA). Review priority: UNKNOWN Marketing status: Discontinued Active ingredient CILASTATIN SODIUM; IMIPENEM Form and strength POWDER;INTRAMUSCULAR - EQ 750MG BASE/VIAL;750MG/VIAL Sponsor MERCK Submission history Latest submission status date: 2009-08-26 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: UNKNOWN
Interaction Notes
- No interaction notes stored yet.